Drug Profile
AZD 3514
Alternative Names: AZD-3514Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 31 Dec 2012 Discontinued - Phase-I for Prostate cancer in Japan (PO)
- 31 Dec 2012 Discontinued - Phase-I for Prostate cancer in Netherlands (PO)
- 31 Dec 2012 Discontinued - Phase-I for Prostate cancer in United Kingdom (PO)